NEW YORK — A new generation of flu vaccines is the most effective and cost-effective way to prevent colds and other viral respiratory infections, according to a report from the National Institutes of Health (NIH).
The report said the vaccines that are currently available can help prevent flu and colds.
The National Institutes report, which is based on the National Health and Nutrition Examination Survey, or NHANES, is one of the first to examine the vaccine efficacy.
A recent study by researchers at the University of Texas School of Public Health found that a flu vaccine was about 85 percent effective in preventing a person from becoming sick.
However, the effectiveness of the vaccine in preventing influenza is limited to about one percent, according the study.
One of the new vaccines, the Pneumovax®3, is being evaluated in the U.S. for use in people who have a history of influenza, such as those who are taking influenza shots or have recently traveled abroad, the study found.
Another new vaccine, the VaxShield™, is designed to protect against COVID-19, which has a high mortality rate among older people.
And the new vaccine is also designed to prevent pneumonia and the respiratory illness that can occur when pneumonia attacks your lungs.
But the researchers noted that some people with milder illnesses, such the elderly, are more likely to benefit from a vaccine.
“It is important to emphasize that there is currently no clear indication that the vaccine has a particular benefit in preventing COVIDs,” the researchers wrote in their report.
Pneumovacys effectiveness is not limited to people who are already sick.
In one study, a group of people with asthma were given a vaccine that protects against COPD, but the researchers said that the results showed that the asthma group did not get better.
More:How the flu vaccine worksThe new vaccine can be given to as many as 10 million people worldwide.
It is manufactured in three phases: Phase 1 is the initial dose and includes a nasal spray; Phase 2 is a nasal swab; and Phase 3 is a shot.
It is administered either by a doctor or by an inhaler.
It is administered over a six-month period, so it is not considered an “early dose.”